European Union - English - EMA (European Medicines Agency)

ecuphar - hydrocortisone aceponate - corticosteroids, dermatological preparations - dogs - for symptomatic treatment of inflammatory and pruritic dermatoses in dogs.for alleviation of clinical signs associated with atopic dermatitis in dogs.

United States - English - NLM (National Library of Medicine)

virbac ah, inc. - hydrocortisone aceponate (unii: 2340up1l2g) (hydrocortisone - unii:wi4x0x7bpj), miconazole nitrate (unii: vw4h1cyw1k) (miconazole - unii:7nno0d7s5m), gentamicin (unii: t6z9v48ikg) (gentamicin - unii:t6z9v48ikg) - hydrocortisone aceponate 1.11 mg in 1 ml - easotic otic suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (malassezia pachydermatis ) and bacteria (staphylococcus pseudintermedius ). do not use in dogs with known tympanic membrane perforation. easotic otic suspension is contraindicated in dogs with known or suspected hypersensitivity to corticosteroids, imidazole antifungals, or aminoglycoside antibiotics.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - hydrocortisone aceponate - unknown - hydrocortisone aceponate steroid-glucocorticoid active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avet health limited - hydrocortisone aceponate - topical solution/suspension - hydrocortisone aceponate steroid-glucocorticoid active 0.584 mg/ml - endocrine system

United Kingdom - English - VMD (Veterinary Medicines Directorate)

ecuphar nv - hydrocortisone aceponate - cutaneous spray, solution - anti inflammatory corticosteroid - dogs

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - hydrocortisone aceponate - unknown - hydrocortisone aceponate steroid-glucocorticoid active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avet health limited - hydrocortisone aceponate - unknown - hydrocortisone aceponate steroid-glucocorticoid active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 5 mg - hydrocortisone tablets, usp are indicated in the following conditions: 1.   endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3.   collagen diseases during an exacerbation or as maintenance therapy in selected cases of:

United States - English - NLM (National Library of Medicine)

greenstone llc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 5 mg - hydrocortisone tablets are indicated in the following conditions. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme (stevens-johnson syndrome) exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: allergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loeffler's syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired (autoimmune) hemolytic anemia erythroblastopenia (rbc anemia) congenital (erythroid) hypoplastic anemia for palliative management of: leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. to tide the patient over a critical period of the disease in: ulcerative colitis regional enteritis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement systemic fungal infections and known hypersensitivity to components

United States - English - NLM (National Library of Medicine)

par pharmaceutical - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 5 mg - hydrocortisone tablets, usp are indicated in the following conditions. - endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer - rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid ar